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 Abstract 
Niosomes are a novel drug delivery system (NDDS), in which the medication is encapsulated in a vesicle. The 
vesicle is composed of a bilayer of non-ionic surface active agents and hence the name niosomes. The niosomes are very 
small, and microscopic in size. Their size lies in the nanometric scale. Although structurally similar to liposomes, they offer 
several advantages over them. It has been a study interest in the development of a NDDS. NDDS has an object to deliver 
the drug at a rate directed by the needs of the body during the period of treatment of a disease, and reach the active 
ingredient to the site of action. A number of NDDS have been reported through various routes of administration, to achieve 
controlled and targeted drug delivery. Encapsulation of the drug in vesicular structures is one of the most important 
systems, which can be predicted to prolong the existence of the drug in systemic circulation and reduce the toxicity, if 
prescribed uptake can be achieved. Consequently a number of vesicular drug delivery systems such as liposomes, 
niosomes, transfersomes, and pharmacosomes were developed. Advances have since been made in the area of vesicular 
drug delivery, leading to the development of systems that allow drug targeting and the sustained or controlled release of 
conventional medicines. The focus of this review is to the various method of preparations, characterization of niosomes, 
advantages and brings out the application vesicular systems. 
Keywords: Niosomes, NDDS, Vesicles, Systemic circulation, Controlled drug release. 
1. Introduction  
Niosomes are non-ionic surfactant vesicles 
obtained on hydration of synthetic nonionic surfactants, 
with or without incorporation of cholesterol or other 
lipids.[1] They are vesicular systems similar to liposomes 
that can be used as carriers of amphiphilic and lipophilic 
drugs. One of the reasons for preparing niosomes is 
assumed higher chemical stability of the surfactants than 
that of phospholipids, which are used in the preparation of 
liposomes. Due to the presence of ester bond, phospholipids 
are easily hydrolysed.[2]
 
Unreliable reproducibility arising 
from the use of lecithin in liposomes leads to additional 
problems and has led scientist to search for vesicles 
prepared from other material, such as nonionic surfactants. 
Niosomes are promising vehicle for drug delivery and being 
nonionic; it is less toxic and improves the therapeutic index 
of drug by restricting its action to target cells. Niosomes or 
non-ionic surfactant vesicles are microscopic lamellar 
structures formed on admixture of non-ionic surfactant of 
the alkyl or dialkyl polyglycerol ether class and cholesterol 
with subsequent hydration in aqueous media.[3] In 
niosomes, the vesicles forming amphiphile is a non-ionic 
surfactant such as Span – 60 which is usually stabilized by 
addition of cholesterol and small amount of anionic 
surfactant such as dicetyl phosphate. 
 
Fig 1: Structure of Niosome (Copied from google.co.in) 
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1.1 Salient Features of Niosomes; 
 Niosomes can entrap solute in a manner analogous to 
Liposome. 
 Niosomes osmoticaly active and stable. 
 Niosomes possess an infra structure consisting of 
hydrophobic and hydrophilic mostly together and so also 
accommodate the drug molecule with a wide range of 
solubility. 
 Niosomes exhibit flexibility in their structural 
charecterestics (composition, fluidity and size) and can be 
designed according to their desired situation. 
 Niosomes can improve the performance of drug 
molecule. 
 Better availability to the particular site, just by protecting 
the drug from biological environment. 
 Niosomes surfactants are biodegradable, biocompatible 
and nonimmunogenic.[1] 
1.2 Advantages of Niosomes 
Use of niosomes in cosmetics was first done by 
L’Oreal as they offered the following advantages [4]: 
 The vesicle suspension being water based offers greater 
patient compliance over oil based systems since the 
structure of the niosome offers place to accommodate 
hydrophilic, lipophilic as well as ampiphilic drug 
moieties, they can be used for a variety of drugs.  
 The characteristics such as size, lamellarity etc. of the 
vesicle can be varied depending on the requirement.  
 The vesicles can act as a depot to release the drug slowly 
and offer a controlled release.  
 They increase the stability of the entrapped drug  
 Handling and storage of surfactants do not require any 
special conditions. 
 Can increase the oral bioavailability of drugs. 
 Can enhance the skin penetration of drugs. 
 They can be used for oral, parenteral as well topical use. 
 Improve the therapeutic performance of the drug by 
protecting it from the biological environment and 
restricting effects to target cells, thereby reducing the 
clearance of the drug.  
 The niosomal dispersions in an aqueous phase can be 
emulsified in a non-aqueous phase to control the release 
rate of the drug and administer normal vesicles in 
external non-aqueous phase.  
 
2. Method of preparation 
2.1 Ether injection method 
This method provides a means of making 
niosomes by slowly introducing a solution of surfactant 
dissolved in diethyl ether into warm water maintained at 
60°C. The surfactant mixture in ether is injected through 
14-gauge needle into an aqueous solution of material. 
Vaporization of ether leads to formation of single layered 
vesicles. Depending upon the conditions used the diameter 
of the vesicle range from 50 to 1000 nm.
 
[5,6] 
2.2 Hand shaking method (Thin film hydration technique) 
The mixture of vesicles forming ingredients like 
surfactant and cholesterol are dissolved in a volatile organic 
solvent (diethyl ether, chloroform or methanol) in a round 
bottom flask. The organic solvent is removed at room 
temperature (20°C) using rotary evaporator leaving a thin 
layer of solid mixture deposited on the wall of the flask. 
The dried surfactant film can be rehydrated with aqueous 
phase at 0-60°C with gentle agitation. This process forms 
typical multilamellar niosomes. Thermo sensitive niosomes 
were prepared by evaporating the organic solvent at 60°C 
and leaving a thin film of lipid on the wall of rotary flash 
evaporator. The aqueous phase containing drug was added 
slowly with intermittent shaking of flask at room 
temperature followed by sonication.
 
[6,7] 
2.3 Sonication  
A typical method of production of the vesicles is 
by Sonication of solution as described by Cable. In this 
method an aliquot of drug solution in buffer is added to the 
surfactant/cholesterol mixture in a 10-ml glass vial. The 
mixture is probe sonicated at 60°C for 3 minutes using a 
sonicater with a titanium probe to yield niosomes.[6,8] 
2.4 Micro fluidization  
Micro fluidization is a recent technique used to 
prepare unilamellar vesicles of defined size distribution. 
This method is based on submerged jet principle in which 
two fluidized streams interact at ultra high velocities, in 
precisely defined micro channels within the interaction 
chamber. The impingement of thin liquid sheet along a 
common front is arranged such that the energy supplied to 
the system remains within the area of niosomes formation. 
The result is a greater uniformity, smaller size and better 
reproducibility of niosomes formed.[9] 
2.5 Multiple membrane extrusion method  
Polycarbonate membranes, which are placed in 
series for upto 8 passages. It is a good method for 
controlling niosome size.Mixture of surfactant, cholesterol 
and dicetyl phosphate in chloroform is made into thin film 
by evaporation. The film is hydrated with aqueous drug 
solution and the resultant suspension extruded through 
which are placed in series for upto 8 passages. It is a good 
method for controlling niosome size.[9] 
2.6 Reverse Phase Evaporation Technique  
Cholesterol and surfactant (1:1) are dissolved in a 
mixture of ether and chloroform. An aqueous phase 
containing drug is added to this and the resulting two 
phases are sonicated at 4-5°C. The clear gel formed is 
further sonicated after the addition of a small amount of 
phosphate buffered saline (PBS). The organic phase is 
removed at 40°C under low pressure. The resulting viscous 
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niosome suspension is diluted with PBS and heated on a 
water bath at 60°C for 10 min to yield niosomes. It 
also have been reported the preparation of Diclofenac 
Sodium niosomes using Tween 85 by this method.[7] 
2.7 Trans membrane pH gradient Drug Uptake Process  
Surfactant and cholesterol are dissolved in 
chloroform. The solvent is then evaporated under reduced 
pressure to get a thin film on the wall of the round bottom 
flask. The film is hydrated with 300 ml citric acid (pH 4.0) 
by vortex mixing. The multilamellar vesicles are frozen and 
thawed 3 times and later sonicated. To this niosomal 
suspension, aqueous solution containing 10 mg/ml of drug 
is added and vortexed. The pH of the sample is then raised 
to 7.0-7.2 with 1M disodium phosphate. This mixture is 
later heated at 60°C for 10 minutes to give niosomes.[10] 
2.8 The “Bubble” Method  
It is novel technique for the one step preparation of 
liposomes and niosomes without the use of organic 
solvents. The bubbling unit consists of round-bottomed 
flask with three necks positioned in water bath to control 
the temperature. Water-cooled reflux and thermometer is 
positioned in the first and second neck and nitrogen supply 
through the third neck. Cholesterol and surfactant are 
dispersed together in this buffer (pH 7.4) at 70°C, the 
dispersion mixed for 15 seconds with high shear 
homogenizer and immediately afterwards “bubbled” at 
70°C using nitrogen gas.[11] 
2.9 Formation of niosomes from proniosomes  
Another method of producing niosomes is to coat a 
water-soluble carrier such as sorbitol with surfactant. The 
result of the coating process is a dry formulation. In which 
each water-soluble particle is covered with a thin film of 
dry surfactant. This preparation is termed “Proniosomes”.  
The niosomes are recognized by the addition of 
aqueous phase at T > Tm and brief agitation.[12] 
T = Temperature. 
Tm = mean phase transition temperature. 
 
 
 
It has been reported the formulation of niosomes 
from maltodextrin based proniosomes. This provides rapid 
reconstitution of niosomes with minimal residual carrier. 
Slurry of maltodextrin and surfactant was dried to form a 
free flowing powder, which could be rehydrated by addition 
of warm water.[12] 
 
3. Separation of unentrapped drug 
The removal of unentrapped solute from the 
vesicles can be accomplished by various techniques, which 
include: - 
3.1 Dialysis 
The aqueous niosomal dispersion is dialyzed in a 
dialysis tubing against phosphate buffer or normal saline or 
glucose solution.[13] 
3.2 Gel Filtration 
The unentrapped drug is removed by gel filtration 
of niosomal dispersion through a Sephadex-G-50 column 
and elution with phosphate buffered saline or normal 
saline.[14,15] 
3.3 Centrifugation 
The niosomal suspension is centrifuged and the 
supernatant is separated. The pellet is washed and then 
resuspended to obtain a niosomal suspension free from 
unentrapped drug.[16,17]
 
 
4. Characterization and factors affecting 
formation of niosomes 
4.1 Nature of surfactants 
A surfactant used for preparation of niosomes 
must have a hydrophilic head and hydrophobic tail. The 
hydrophobic tail may consist of one or two alkyl or 
perfluoroalkyl groups or in some cases a single steroidal 
group[18]. The ether type surfactants with single chain 
alkyl as hydrophobic tail is more toxic than corresponding 
dialkylether chain .The ester type surfactants are chemically 
less stable than ether type surfactants and the former is less 
toxic than the latter due to ester-linked surfactant degraded 
by esterases to triglycerides and fatty acid in vivo.[19] The 
surfactants with alkyl chain length from C12-C18 are 
suitable for preparation of noisome [20,21]. 
4.2 Structure of surfactants 
The geometry of vesicle to be formed from 
surfactants is affected by its structure, which is related to 
critical packing parameters. On the basis of critical packing 
parameters of surfactants can predicate geometry of vesicle 
to be formed. Critical packing parameters can be defined 
using following equation, 
CPP (Critical Packing Parameters) =v /lc*a0where v = 
hydrophobic group volume, lc = the critical hydrophobic 
group length, a0 = the area of hydrophilic head group. 
From the critical packing parameter value type of 
miceller structure formed can be ascertained as given 
below, 
If CPP < ½ then formation of spherical micelles, 
If ½ < CPP < 1 formation of bilayer micelles, 
If CPP > 1 formation inverted micelles.[22]
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4.3 Membrane composition 
The stable niosomes can be prepared with addition 
of different additives along with surfactants and drugs. 
Niosomes formed have a number of morphologies and their 
permeability and stability properties can be altered by 
manipulating membrane characteristics by different 
additives. In case of polyhedral niosomes formed from 
C16G2, the shape of these polyhedral niosome remains 
unaffected by adding low amount of solution C24 
(cholesteryl poly-24-oxyethylene ether), which prevents 
aggregation due to development of steric hindrance[23]. 
4.4 Nature of encapsulated drug 
The physicochemical properties of encapsulated 
drug influence charge and rigidity of the niosome bilayer. 
The drug interacts with surfactant head groups and develops 
the charge that creates mutual repulsion between surfactant 
bilayers and hence increases vesicle size.[24] 
4.5 Temperature of hydration 
Hydration temperature influences the shape and 
size of the noisome. For ideal condition it should be above 
the gel to liquid phase transition temperature of system. 
Temperature change of niosomal system affects assembly 
of surfactants into vesicles and also induces vesicle shape 
transformation.[25] 
4.6 Bilayer formation 
Assembly of non-ionic surfactants to form bilayer 
vesicle is characterized by X-cross formation under light 
polarization microscopy.[26] 
4.7 Number of lamellae 
It is determined by using NMR spectroscopy, 
small angle X-ray scattering and electron microscopy.[27] 
4.8 Membrane rigidity 
Membrane rigidity can be measured by means of 
mobility of fluorescence probe as function of 
temperature.[26] 
4.9 Entrapment efficiency (EE) 
The entrapment efficiency (EE) is expressed as EE 
= amount entrapped/total amount added 100. It is 
determined after separation of unentrapped drug, on 
complete vesicle disruption by using about 1ml of 2.5% 
sodium lauryl sulfate, briefly homogenized and centrifuged 
and supernatant assayed for drug after suitable dilution[28]. 
Entrapment efficiency is affected by following factors. 
a. Surfactants 
The chain length and hydrophilic head of nonionic 
surfactants affect entrapment efficiency, such as stearyl 
chain C18 non-ionic surfactant vesicles show higher 
entrapment efficiency than lauryl chain C12 non-ionic 
surfactant vesicles. The tween series surfactants bearing a 
long alkyl chain and a large hydrophilic moiety in the 
combination with cholesterol at1:1 ratio has highest 
entrapment efficiency for water soluble drugs[26]. HLB 
value of surfactants affects entrapment efficiency, such as 
HLB value of 14 to 17 is not suitable for niosomes but HLB 
value of 8.6 has highest entrapment efficiency and 
entrapment efficiency decreases with decrease in HLB 
value from 8.6 to 1.7.[29]
 
4.10 Cholesterol contents 
The incorporation of cholesterol into bilayer 
composition of niosome induces membrane stabilizing 
activity and decreases the leakiness of membrane.[30]
 
Hence, incorporation of cholesterol into bilayer increases 
entrapment efficiency. The permeability of vesicle bilayer 
to 5, 6-carboxy flourescein (CF) is reduced by 10 times due 
to incorporation of cholesterol.[31]
 
 
5. Applications of niosomes 
5.1 Niosomes as Drug Carriers  
A number of workers have reported the 
preparation, characterization and use of niosomes as drug 
carriers. Niosomes containing anti-cancer drugs, if suitably 
designed, will be expected to accumulate within tumors in a 
similar manner to liposomes. The niosomal encapsulation 
of Methotrexate and Doxorubicin increases drug delivery to 
the tumor and tumoricidal activity of the drug. Doxorubicin 
niosomes possessing muramic acid and triglycerol surfaces 
were not taken up significantly by liver. The triglycerol 
niosomes accumulated in the tumor and muramic acid 
vesicles accumulated in the spleen. Those vesicles with 
polyoxyethylene surface were rapidly taken up by the liver 
and accumulated to a lesser extent in tumor. Baillie et 
al[32] investigated the encapsulation and retention of 
entrapped solute 5,6-carboxy fluorescence (CF) in 
niosomes. They observed that stable vesicles could not be 
formed in the absence of cholesterol but were more 
permeable to entrapped solute. The physical characteristics 
of the vesicles were found to be dependent on the method 
of production. Chandraprakash et al[33] reported the 
formation and pharmacokinetic evaluation of Methotrexate 
niosomes in tumor bearing mice. Cable et al[34] modified 
the surface of niosomes by incorporating polyethylene alkyl 
ether in the bilayered structure. They compared the release 
pattern and plasma level of Doxorubicin in niosomes and 
Doxorubicin mixed with empty niosomes and observed a 
sustained and higher plasma level of doxorubicin from 
niosomes in mice. D’ Souza et al[35] studied absorption of 
Ciprofloxacin and Norfloxacin when administered as 
niosome encapsulated inclusion complexes. Raja Naresh et 
al[36] reported the anti-inflammatory activity of niosome 
encapsulated Diclofenac sodium in arthritic rats. It was 
found that the niosomal formulation prepared by employing 
a 1:1 combination of Tween 85 elicited a better consistent 
anti-inflammatory activity for more that 72 hrs after 
administration of single dose. Carter et al[37] reported that 
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multiple dosing with sodium stibogluconate loaded 
niosomes was found to be effective against parasites in the 
liver, spleen and bone marrow as compared to simple 
solution of sodium stibogluconate. Namdeo et al[38] 
reported the formulation and evaluation of Indomethacin 
loaded niosomesand showed that therapeutic effectiveness 
increased and simultaneously toxic side effect reduced as 
compared with free Indomethacin in paw edema bearing 
rats. Parthasarthi et al[39] prepared niosomes of vincristine 
sulfate which had lesser toxicity and improved anticancer 
activity. Jagtap and Inamdar prepared niosomes of 
Pentoxifylline and studied the in-vivo bronchodilatory 
activity in guinea pigs. The entrapment efficiency was 
found to be 9.26 ± 1.93% giving a sustained release of drug 
over a period of 24 hrs. Azmin et al[40] reported the 
preparation and oral as well as intravenous administration 
of Methotrexate loaded niosomes in mice. They observed 
significant prolongation of plasma levels and high uptake of 
Methotrexate in liver from niosomes as compared to free 
drug solution. 
5.2 Diagnostic imaging with niosomes 
Niosomal system can be used as diagnostic agents. 
Conjugated niosomal formulation of 
gadobenatedimeglcemine with [N-palmitoylglucosamine 
(NPG)], PEG 4400, and both PEG and NPG exhibit 
significantly improved tumor targeting of an encapsulated 
paramagnetic agent assessed with MR imaging.[41] 
5.3 Ophthalmic drug delivery 
Bioadhesive-coated niosomal formulation of 
acetazolamide prepared from span 60, cholesterol 
stearylamine or dicetyl phosphate exhibits more tendency 
for reduction of intraocular pressure as compared to 
marketed formulation (Dorzolamide) The 
chitosancoatedniosomal formulation timolol maleate 
(0.25%) exhibits more effect for reduction intraocular 
pressure as compared to a marketed formulation with less 
chance of cardiovascular side effects.[42] 
 
6. Targeting of bioactive agents 
a) To reticulo-endothelial system (RES) 
The cells of RES preferentially take up the 
vesicles. The uptake of niosomes by the cells is also by 
circulating serum factors known as opsonins, which mark 
them for clearance. Such localized drug accumulation has, 
however, been exploited in treatment of animal tumors 
known to metastasize to the liver and spleen and in parasitic 
infestation of liver.[43] 
b) To organs other than RES 
It has been suggested that carrier system can be 
directed to specific sites in the body by use of 
antibodies.[44]
 
Immunoglobulins seem to bind quite readily 
to the lipid surface, thus offering a convenient means for 
targeting of drug carrier. Many cells possess the intrinsic 
ability to recognize and bind particular carbohydrate 
determinants and this can be exploited to direct carriers 
system to particular cells.  
Delivery of peptide drugs 
Yoshida et al[45] investigated oral delivery of 9-
desglycinamide, 8-arginine vasopressin entrapped in 
niosomes in an in-vitro intestinal loop model and reported 
that stability of peptide increased significantly. 
Neoplasia 
Doxorubicin, the anthracyclic antibiotic with broad 
spectrum anti tumor activity, shows a dose dependant 
irreversible cardio toxic effect. Niosomal delivery of this 
drug to mice bearing S-180 tumor increased their life span 
and decreased the rate of proliferation of sarcoma [58]. 
Niosomal entrapment increased the half-life of the drug, 
prolonged its circulation and altered its metabolism. 
Intravenous administration of methotrexate entrapped in 
niosomes to S-180 tumor bearing mice resulted in total 
regression of tumor and also higher plasma level and slower 
elimination [46,47]. Immunological application of 
niosomes. Niosomes have been used for studying the nature 
of the immune response provoked by antigens. Brewer and 
Alexander [48] have reported niosomes as potent adjuvant 
in terms of immunological selectivity, low toxicity and 
stability. 
Transdermal delivery of drugs by niosomes 
Slow penetration of drug through skin is the major 
drawback of transdermal route of delivery. An increase in 
the penetration rate has been achieved by transdermal 
delivery of drug incorporated in niosomes. Jayraman et 
al[49] has studied the topical delivery of erythromycin from 
various formulations including niosomes or hairless mouse. 
From the studies, and confocal microscopy, it was seen that 
non-ionic vesicles could be formulated to target 
pilosebaceous glands. 
Niosome formulation as a brain targeted  
Niosomaldelivery system for the vasoactive 
intestinal peptide (VIP)Radiolabelled (I125) VIP-loaded 
glucosebearing niosomes were injected intravenously to 
mice. Encapsulated VIP within glucosebearing niosomes 
exhibits higher VIP brain uptake as compared to 
control.[50] 
Niosomes as carriers for Hemoglobin. 
Niosomes can be used as a carrier for hemoglobin. 
Niosomal suspension shows a visible spectrum 
superimposable onto that of free hemoglobin. Vesicles are 
permeable to oxygen and hemoglobin dissociation curve 
can be modified similarly to non-encapsulated 
hemoglobin.[51,52]
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Table 1: Drugs Incorporated into Niosomes by Various 
Methods 
Method of 
Preparation 
Drug Incorporated 
Ether Injection Sodium stibogluconate [53,54], Doxorubicin 
Hand Shaking Methotrexate[55],Doxorubicin 
Sonication 9desglycinamide,arginine,Vasopressin,Oestr
adiol[56] 
 
7. Comparison between niosomes and liposome 
Niosomes are made of non-ionic surfactants and 
cholesterol. Most surfactants have a single hydrophobic tail, 
eg: sodium dodecyl sulphate. On the other hand liposomes 
are made of phospholipids, they may or may not contain 
cholesterol. Phospholipids have two hydrophobic tails.[3] 
Since niosomes are prepared from uncharged 
single-chain surfactant and cholesterol, whereas liposomes 
are prepared from double-chain phospholipids (neutral or 
charged). The concentration of cholesterol in liposomes is 
much more than that in niosomes. As a result, drug 
entrapment efficiency of liposomes becomes lesser than 
niosomes because the intercalation of cholesterol in the 
bilayers decreases the entrapment volume during 
formulation and thus entrapment efficiency.[57] 
Niosomes behave in vivo like liposomes, 
prolonging the circulation of entrapped drug and altering its 
organ distribution and metabolic stability.[58] 
Due to presence of hydrophilic, amphiphilic and 
lipophilic moieties in the structure, these can accommodate 
drug molecules with a wide range of solubility comparision 
to liposome.[59] 
Niosomes are usually more stable towards 
oxidative degradation because liposome’s phospholipids are 
more prone to oxidative degradation. 
Niosomes are inexpensive and easier to make and 
store whereas liposomes are expensive and they require 
special storage and handling.[60] 
 
8. Conclusion 
It is obvious that niosome appears to be a well 
preferred drug delivery system over liposome as niosome 
being stable and economic. Also niosomes have great drug 
delivery potential for targeted delivery of anti-cancer, 
antiinfectiveagents. Drug delivery potential of niosome can 
enhance by using novel concepts like proniosomes, 
discomes and aspasome. Niosomes also serve better aid in 
diagnostic imaging and as a vaccine adjuvant. Thus these 
areas need further exploration and research so as to bring 
out commercially available niosomal preparation. The 
concept of incorporating the drug into liposomes or 
niosomes for a better targeting of the drug at appropriate 
tissue destination is widely accepted by researchers and 
academicians. Niosomes represent a promising drug 
delivery module. They present a structure similar to 
liposome and hence they can represent alternative vesicular 
systems with respect to liposomes, due to the niosome 
ability to encapsulate different type of drugs within their 
multienvironmental structure. Niosomes are thoughts to be 
better candidate drug delivery as compared to liposomes 
due to various factors like cost, stability etc. Various type of 
drug deliveries can be possible using niosomes like 
targeting, ophthalmic, topical, parenteral. 
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